# US 2024/0197699 A1 · Benzomorphan derivate for use in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197699 A1
- Document ID: US20240197699A1
- Status: Published application
- Kind: A1
- Application number: 18/553,514
- Filed: 2022-03-30
- Published: 2024-06-20
- Earliest claimed: 2021-03-30
- Assignees: Molecular Research Pharmact S.R.L.
- Applicants: Molecular Research Pharmact S.R.L.
- Inventors: Salvatore GUCCIONE; Simone RONSISVALLE; Livia BASILE; Matteo PAPPALARDO; Danilo MILARDI; Angelo SPADARO; Chun Laam NG
- Web page: https://patentgrep.com/patent/US20240197699A1

## CPC

- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 25/02: for peripheral neuropathies
- A61P 27/00: Drugs for disorders of the senses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compound with formula (1) suitable for use in a method for treating a disease or disorder capable of being treated by an agonist of AdipoR. e.g. diabetic neuropathy. Also disclosed are related pharmaceutical compositions and medicaments, as well as a method for treatment of disorders including administering such compound, pharmaceutical composition, or medicament.

## Claims

### Claim 1

Compound of formula (1)
Suitable for use in the treatment of a disease or disorder capable of being treated by an agonist of AdipoR.

### Claim 2 (depends on 1)

The compound of claim 1 wherein AdipoR is AdipoR1 and/or AdipoR2.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the disease or disorder is a metabolic disease or disorder.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the disease or disorder is selected from obesity, atherosclerosis, dyslipidaemia and non-alcoholic fatty liver disease.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the disease or disorder comprises hyperglycaemia.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the disease or disorder is selected from diabetes, diabetic nephropathy, and diabetic retinopathy

### Claim 7 (depends on 1)

The compound of claim 1, wherein the disease or disorder is diabetic neuropathy.

### Claim 8 (depends on 1)

The compound of claim 1, suitable for use in mammals.

### Claim 9 (depends on 1)

The compound of claim 1, suitable for use in humans.

### Claim 10

Pharmaceutical composition comprising the compound of formula (1) and pharmaceutically acceptable excipients

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10 in the form of a solution, suspension, powder, granule, tablet, pill, capsule, syrup, suppository, spray, aerosol, controlled-release system, cream, ointment, gel, lubricant, paste, syrup, ampoule, phial, drop or eye drop.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10 suitable for use in the treatment of a disease or disorder capable of being treated by an agonist of AdipoR.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12 wherein AdipoR is AdipoR1 and/or AdipoR2.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease or disorder is a metabolic disease or disorder.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease or disorder is selected from obesity, atherosclerosis, dyslipidaemia and non-alcoholic fatty liver disease.

### Claim 16 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease or disorder comprises hyperglycaemia.

### Claim 17 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease or disorder is selected from diabetes, diabetic nephropathy, and diabetic retinopathy.

### Claim 18 (depends on 12)

The pharmaceutical composition of claim 12, wherein the disease or disorder is diabetic neuropathy

### Claim 19 (depends on 10)

The pharmaceutical composition of claim 10, suitable for use in the treatment of a disease or disorder capable of being treated by an agonist of AdipoR in mammals.

### Claim 20 (depends on 10)

The pharmaceutical composition as defined of claim 10, suitable for use in the treatment of a disease or disorder capable of being treated by an agonist of AdipoR in humans.

### Claim 21 (depends on 10)

The pharmaceutical composition as defined according to claim 10, suitable for use in the treatment of a disease or disorder capable of being treated by an agonist of AdipoR, to be administered orally, transdermally, subcutaneously, intravenously, rectally or intranasally.

### Claim 22 (depends on 1)

A method of treating a disease or disorder capable of being treated by an agonist of AdipoR the method comprising administering to a subject in need thereof an effective amount of the compound of claim 1 or a pharmaceutical composition comprising the compound of claim 1.

### Claim 23 (depends on 1)

A medicament suitable for the treatment of a disease or disorder capable of being treated by an agonist of AdipoR, the medicament comprising the compound of claim 1 or a pharmaceutical composition comprising the composition of claim 1.
